Interventions
toxicity, toxicities, tumor, celiac trunk lymph node
ADVERSE EVENTS, TUMOR, RECURRENCE, METASTASIS
Patients who met the eligible criteria received concurrent chemoradiotherapy. Radiotherapy began on day 1, concurrent with the beginning of cycle 1 of chemotherapy. Radiotherapy was delivered with photons (≥ 6 MV) from a linear accelerator to a total dose of 45 Gy in 25 fractions. Patients were treated 5 days per week at 1.8 Gy/day. Intensity modulated radiotherapy was required. The definition of clinical target volume (CTV) included tumor bed, anastomosis site, bilateral supraclavicular region, all mediastinal lymph node site, left gastric and celiac trunk lymph node site. The superior, inferior, anterior, posterior and lateral borders of planning target volume (PTV) were 1 cm beyond CTV. The field next to the spinal cord could be slightly adjusted in order to reduce the exposure of spinal cord. (Additional file When formulating the treatment plan, normal organ dose restrictions should be taken into consideration (Additional file All patients were planned to be treated with 5 cycles of weekly chemotherapy concurrent with radiotherapy. The chemotherapy regimen consisted of paclitaxel (50 mg/mPatients were followed-up at least weekly in the course of postoperative chemoradiotherapy to monitor the adverse events. If grade 3 or higher hematological and non-hematological toxicities was observed, radiotherapy had to be suspended until toxicity no more than grade 2. If neutrophil count < 1.5 × 10After the completion of all treatment, patients were evaluated for evidence of local recurrence and distant metastasis every 3 months within the first 2 years, every 6 months for the next 3 years and once a year thereafter. Chest CT scan with contrast, neck and abdomen ultrasound, esophagography (barium swallow) should be processed as routine and esophagoscopy when necessary. Investigators reviewed all the results of the examinations above and made assessments.